文献速递艾滋病与性传播感染

多替拉韦联合抗逆转录病毒治疗围产期HIV-1感染青少年的疗效与耐受性:法国多中心回顾性研究

Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

该法国多中心回顾性研究纳入50例围产期HIV-1感染青少年,评估基于多替拉韦方案的安全性和疗效。结果显示66%患者维持持续病毒学成功,78%末次随访时PVL不可测,多替拉韦耐受性良好,仅1例因严重药物相关不良反应停药。

要点

  • 基线病毒学抑制的17例中14例(82%)维持抑制,3例短暂反弹后恢复。
  • 33例基线可检测病毒载量者中19例(58%)获得并维持病毒学成功。
  • 仅1例因头晕和睡眠障碍停用多替拉韦,失败者未出现耐药突变。

核心结论

  • 多替拉韦方案在这些围产期HIV-1感染青少年中安全且病毒学有效。
  • 需多种干预措施以提高依从性。

研究设计与样本

  • 收集多替拉韦启动前后的临床和生物学数据分析。

主要发现

  • 基线时17/50例青少年已达到病毒学抑制。
  • 基线病毒学抑制者中14/17例(82%)维持病毒学成功,3例出现短暂病毒反弹后PVL再次降至<50 copies/mL,无需更换方案。
  • 33例基线可检测病毒载量者中19/33例(58%)获得并维持病毒学成功;另3例初始病毒学失败者在加强依从性措施后末次随访PVL不可测。
  • 总体66%患者持续病毒学成功,78%患者末次随访PVL不可测。
  • 仅1例因严重药物相关不良反应(头晕和睡眠障碍)停药;病毒学失败者中未观察到耐药突变出现。

关键数值与推荐

  • 主要终点:基线可检测病毒载量者在多替拉韦启动3个月内达到PVL<50 copies/mL,且所有患者维持病毒学抑制至末次随访。
  • 病毒学成功定义为PVL<50 copies/mL。

临床怎么用

  • 多替拉韦方案可用于围产期HIV-1感染青少年的治疗,需关注依从性支持。
  • 治疗过程中应监测病毒载量,病毒学失败时需加强依从性干预。

局限性

  • 回顾性研究设计。
  • 样本量较小(50例)。
  • 未报告对照方案比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the safety and efficacy of a dolutegravir-based regimen in perinatally HIV-1-infected adolescents. PATIENTS AND METHODS: We conducted a retrospective multicentre study of 50 adolescents beginning dolutegravir-based treatment regimens between January 2014 and December 2015. Clinical and biological data collected before and after dolutegravir initiation were analysed. The primary endpoint was the proportion of patients achieving a plasma viral load (PVL) <50 copies/mL within 3 months of dolutegravir initiation (for patients with detectable viraemia at baseline) and maintaining virological suppression (PVL <50 copies/mL) until the last follow-up visit (for all patients). RESULTS: Virological suppression was noted for 17/50 adolescents at baseline. Dolutegravir-based regimens maintained virological success in 14/17 patients (82%). The other three patients experienced a transient viral rebound, before PVL fell to < 50 copies/mL again, with no need to change the antiretroviral regimen. Thirty-three viraemic adolescents were enrolled. All but one had already received antiretroviral drugs. Virological success was achieved and maintained in 19/33 subjects (58%). Another three adolescents with initial virological failure had an undetectable PVL at the end of follow-up, with reinforced measures to improve compliance. Overall, sustained virological success was observed in 66% of patients and 78% of patients had an undetectable PVL at the last visit. Dolutegravir was well tolerated. Only one patient stopped treatment for severe drug-related adverse effects (dizziness and sleep disturbance). No emergence of resistance mutations was observed in patients with virological failure. CONCLUSIONS: Dolutegravir was safe and virologically effective in these patients, for whom multiple interventions were required to improve compliance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Briand C, Dollfus C, Faye A, et al. Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study. J Antimicrob Chemother. 2017. PMID: 27999017. doi:10.1093/jac/dkw464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。